• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma.

作者信息

Personeni Nicola, Pressiani Tiziana, Rimassa Lorenza

机构信息

Department of Biomedical Sciences Humanitas University Pieve Emanuele Italy.

Humanitas Cancer Center Humanitas Clinical and Research Center-IRCCS Rozzano Italy.

出版信息

Health Sci Rep. 2020 Jan 29;3(1):e147. doi: 10.1002/hsr2.147. eCollection 2020 Mar.

DOI:10.1002/hsr2.147
PMID:32166192
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7060890/
Abstract
摘要

相似文献

1
Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma.当有多种疗法可供选择时，该如何抉择？晚期肝细胞癌的当前全身治疗方法。
Health Sci Rep. 2020 Jan 29;3(1):e147. doi: 10.1002/hsr2.147. eCollection 2020 Mar.
2
Systemic Therapy in Metastatic Hepatocellular Carcinoma.转移性肝细胞癌的系统治疗。
Curr Gastroenterol Rep. 2022 May;24(5):65-71. doi: 10.1007/s11894-022-00842-9. Epub 2022 Apr 13.
3
Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.钇-90微球放射性栓塞治疗不可切除的肝细胞癌
Cochrane Database Syst Rev. 2016 Feb 16;2:CD011313. doi: 10.1002/14651858.CD011313.pub2.
4
A Review of Current and Emerging Therapies for Advanced Hepatocellular Carcinoma.晚期肝细胞癌的现有和新兴治疗方法综述。
Curr Oncol. 2022 Sep 8;29(9):6445-6462. doi: 10.3390/curroncol29090507.
5
Systemic therapy of advanced hepatocellular carcinoma.晚期肝细胞癌的系统治疗。
Future Oncol. 2021 Apr;17(10):1237-1251. doi: 10.2217/fon-2020-0758. Epub 2020 Dec 14.
6
Systemic therapy for advanced hepatocellular carcinoma: targeted therapies.晚期肝细胞癌的系统治疗：靶向治疗。
Chin Clin Oncol. 2021 Feb;10(1):10. doi: 10.21037/cco-20-117. Epub 2020 May 14.
7
Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure.肝细胞癌的二线全身治疗：失败原因
World J Hepatol. 2015 Aug 18;7(17):2053-7. doi: 10.4254/wjh.v7.i17.2053.
8
Current and Future Systemic Therapies for Hepatocellular Carcinoma.肝细胞癌的当前及未来全身治疗方法
Gastroenterol Hepatol (N Y). 2019 May;15(5):266-272.
9
Systemic therapy for hepatocellular carcinoma: current status and future perspectives.肝细胞癌的系统治疗：现状与未来展望
Jpn J Clin Oncol. 2021 Aug 30;51(9):1363-1371. doi: 10.1093/jjco/hyab108.
10
New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma.中晚期肝细胞癌的系统治疗新治疗模式。
Int J Clin Oncol. 2022 Jul;27(7):1110-1119. doi: 10.1007/s10147-022-02166-0. Epub 2022 May 8.

引用本文的文献

1
Novel Therapies for Hepatocellular Carcinoma.肝细胞癌的新型治疗方法
Cancers (Basel). 2020 Oct 20;12(10):3049. doi: 10.3390/cancers12103049.

本文引用的文献

1
Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma.基于血浆生物标志物的卡博替尼对比安慰剂治疗晚期肝细胞癌的3期CELESTIAL试验结果
Liver Cancer. 2021 Dec 3;11(1):38-47. doi: 10.1159/000519867. eCollection 2022 Jan.
2
Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma.一线使用乐伐替尼后序贯全身抗癌药物的疗效：来自不可切除肝细胞癌3期REFLECT研究的事后应答者分析
Liver Cancer. 2020 Jan;9(1):93-104. doi: 10.1159/000504624. Epub 2019 Dec 16.
3
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.帕博利珠单抗作为 KEYNOTE-240 中晚期肝细胞癌二线治疗的疗效：一项随机、双盲、III 期试验。
J Clin Oncol. 2020 Jan 20;38(3):193-202. doi: 10.1200/JCO.19.01307. Epub 2019 Dec 2.
4
Role of liver biopsy in hepatocellular carcinoma.肝活检在肝细胞癌中的作用。
World J Gastroenterol. 2019 Oct 28;25(40):6041-6052. doi: 10.3748/wjg.v25.i40.6041.
5
Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study.美国肝癌患者经动脉化疗栓塞术后肝功能变化：LiverT 研究。
BMC Cancer. 2019 Aug 13;19(1):795. doi: 10.1186/s12885-019-5989-2.
6
Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma.与肝癌患者对regorafenib 反应相关的生物标志物。
Gastroenterology. 2019 May;156(6):1731-1741. doi: 10.1053/j.gastro.2019.01.261. Epub 2019 Feb 6.
7
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.瑞戈非尼治疗后索拉非尼治疗失败的晚期肝细胞癌患者的 Ramucirumab（REACH-2）：一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet Oncol. 2019 Feb;20(2):282-296. doi: 10.1016/S1470-2045(18)30937-9. Epub 2019 Jan 18.
8
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.卡博替尼治疗晚期和进展性肝细胞癌患者。
N Engl J Med. 2018 Jul 5;379(1):54-63. doi: 10.1056/NEJMoa1717002.
9
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.帕博利珠单抗治疗索拉非尼治疗后晚期肝细胞癌患者（KEYNOTE-224）：一项非随机、开放标签的 2 期试验。
Lancet Oncol. 2018 Jul;19(7):940-952. doi: 10.1016/S1470-2045(18)30351-6. Epub 2018 Jun 3.
10
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.序贯索拉非尼后regorafenib 治疗 HCC 的结果：来自 III 期 RESORCE 试验的附加分析。
J Hepatol. 2018 Aug;69(2):353-358. doi: 10.1016/j.jhep.2018.04.010. Epub 2018 Apr 26.